Cited by 9Renal Diseases and GlomerulopathiesChronic Kidney Disease and DiabetesLipid metabolism and disorders

A novel apolipoprotein E mutation caused by a five amino acid deletion in a Chinese family with lipoprotein glomerulopathy: a case report

Open access
Xie, Weiji, Xie, Yi, Lin, Zhijun, Xu, Xiaochang, Zhang, Yimin·2019·Diagnostic Pathology

Abstract

BACKGROUND: Lipoprotein glomerulopathy (LPG) is a rare kidney disease with a poor prognosis that is related to mutation of the apoE gene. More than 10 variants of apoE associated with LPG have currently been identified. CASE PRESENTATION: A male and his mother presented with proteinuria during a health examination. They went to hospital for further examination. Renal biopsy was performed, and the diagnosis was lipoprotein glomerulopathy (LPG), which is a rare, inherited renal disease. Medical histories were collected from the 2 LPG patients and their family members. The patients and family members underwent a routine urine test, and their renal function, blood lipids, and lipoprotein levels were examined. Genomic DNA was extracted from the peripheral blood of 7 family members, and exon 2, exon 3 and exon 4 of apoE were amplified by polymerase chain reaction (PCR). The purified PCR products were sequenced. Sequence analysis identified a 15 bp deletion (GCGCAAGCTGCGTAA) in exon 4 of the apoE gene that results in a novel 5 amino acid deletion in apoE (143 K-147R → 0). No mutations were found in exon 2 and exon 3 of the apoE gene. CONCLUSIONS: This family study suggests that a novel ApoE mutation (143 K-147R → 0) may be etiologically related to LPG, and other genetic or environmental factors may be associated with the occurrence of LPG.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13000-019-0820-6

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 24

  1. [2]Saito T Matsunaga A Ito K Nakashima H Topics in lipoprotein glomerulopathy: an overview Clin Exp Nephrol 2014 18 2 214 217 10.1007/s10157-013-0887-4 24149835 · DOI · Paper page
  2. [3]Saito T Matsunaga A Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis Kidney Int 2014 85 2 243 245 10.1038/ki.2013.404 24487366 · DOI · Paper page
  3. [4]Kinomura M Sugiyama H Saito T A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy Nephrol Dial Transplant 2008 23 2 751 756 10.1093/ndt/gfm675 18045818 · DOI · Paper page
  4. [5]Tsimihodimos V Elisaf M Lipoprotein glomerulopathy Curr Opin Lipidol 2011 22 4 262 269 10.1097/MOL.0b013e328345ebb0 21464714 · DOI · Paper page
  5. [6]Bomback AS Song H D'Agati VD A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy Nephrol Dial Transplant 2010 25 10 3442 3446 10.1093/ndt/gfq389 20624773 · DOI · Paper page
  6. [7]Oikawa S Matsunaga A Saito T Apolipoprotein E Sendai (arginine 145-->proline): a new variant associated with lipoprotein glomerulopathy J Am Soc Nephrol 1997 8 5 820 823 9176854
  7. [8]Ishimura A Watanabe M Nakashima H Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice Clin Exp Nephrol 2009 13 5 430 437 10.1007/s10157-009-0195-1 19459027 · DOI · Paper page
  8. [9]Matsunaga A Sasaki J Komatsu T A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy Kidney Int 1999 56 2 421 427 10.1046/j.1523-1755.1999.00572.x 10432380 · DOI · Paper page
  9. [10]Hagiwara M Yamagata K Matsunaga T A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy Nephrol Dial Transplant 2008 23 1 381 384 10.1093/ndt/gfm735 17967799 · DOI · Paper page
  10. [11]Sam R Wu H Yue L Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding Am J Kidney Dis 2006 47 3 539 548 10.1053/j.ajkd.2005.12.031 16490634 · DOI · Paper page
  11. [12]Cautero N Di BF De Ruvo N Novel genetic mutation in apolipoprotein E2 homozygosis and its implication in organ donation: a case report Transplant Proc 2010 42 4 1349 1351 10.1016/j.transproceed.2010.03.104 20534298 · DOI
  12. [13]Luo B Huang F Liu Q Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy Am J Nephrol 2008 28 2 347 353 10.1159/000111828 18046082 PMC2785906 · DOI · Paper page
  13. [14]Tokura T Itano S Kobayashi S A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy J Atheroscler Thromb 2011 18 6 536 541 10.5551/jat.8102 21467726 · DOI · Paper page
  14. [16]Cheung CY Chan AO Chan YH A rare cause of nephrotic syndrome: lipoprotein glomerulopathy Hong Kong Med J 2009 15 1 57 60 10.1177/102490790801500111 19197098 · DOI
  15. [17]Konishi K Saruta T Kuramochi S Association of a novel 3-amino acid deletion mutation of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy Nephron. 1999 83 3 214 218 10.1159/000045513 10529627 · DOI · Paper page
  16. [18]Ogawa T Maruyama K Hattori H A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy Pediatr Nephrol 2000 14 2 149 151 10.1007/s004670050032 10684367 · DOI · Paper page
  17. [19]Huang Y Mahley RW Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases Neurobiol Dis 2014 72 Pt A 3 12 10.1016/j.nbd.2014.08.025 25173806 PMC4253862 · DOI · Paper page
  18. [20]Hoffmann M Scharnagl H Panagiotou E Banghard W Wieland H März W Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy J Am Soc Nephrol 2001 12 3 524 530 11181800
  19. [21]Russi G Furci L Leonelli M Lipoprotein glomerulopathy treated with LDL-apheresis (heparin-induced extracorporeal lipoprotein precipitation system): a case report J Med Case Rep 2009 3 9311 10.1186/1752-1947-3-9311 20062740 PMC2803834 · DOI · Paper page
  20. [22]Pham T Kodvawala A Hui DY The receptor binding domain of apolipoprotein E is responsible for its antioxidant activity Biochemistry. 2005 44 20 7577 7582 10.1021/bi0472696 15896001 · DOI
  21. [23]Ando M Sasaki J Hua H A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy Kidney Int 1999 56 4 1317 1323 10.1046/j.1523-1755.1999.00677.x 10504484 · DOI · Paper page
  22. [24]Saito T Matsunaga A Oikawa S Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases Am J Kidney Dis 2006 47 2 199 211 10.1053/j.ajkd.2005.10.017 16431249 · DOI · Paper page
  23. [25]Hu Z Huang S Wu Y Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation Kidney Int 2014 85 2 416 424 10.1038/ki.2013.335 24025644 · DOI · Paper page
  24. [26]Ito K Nakashima H Watanabe M Macrophage impairment produced by fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities Nephrol Dial Transplant 2012 27 10 3899 3907 10.1093/ndt/gfs329 22863838 · DOI · Paper page

Cited by

Sorted by citations

Authors
Xie, W., Xie, Y., Lin, Z., Xu, X., & Zhang, Y.
Affiliations
  • Shantou University (CN)
  • Sixth Affiliated Hospital of Sun Yat-sen University (CN)
Corresponding author
Zhang, Yimin
Venue
Diagnostic Pathology
Published
2019-05-15
Volume
14
Issue
1
Pages
41-41
ISSN
1746-1596 (ISSN-L)
OpenAlex
W2947797031
Cited by
9
References
2
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2022: 3 · 2021: 1 · 2019: 1
FWCI
0.96
Type
journal article
Language
en
Open access
Locations
  • Diagnostic Pathology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Science and Technology Planning Project of Guangdong Province
Topics
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
lipoprotein glomerulopathy, apolipoprotein E, novel mutations, exon 4, proteinuria, hereditary kidney disease, familial case, Chinese family
MeSH terms
Amino Acids, Apolipoproteins E, Exons, Female, Humans, Kidney, Kidney Diseases, Kidney Glomerulus, Lipids, Male, Mutation, Pedigree, Sequence Deletion, Asian People

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review